Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., . . . Gonzalez, E. E. (2012). Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. The lancet oncology, 13(3), 300-308. https://doi.org/10.1016/S1470-2045(11)70385-0
Citace podle Chicago (17th ed.)Ciuleanu, Tudor, Lilia Stelmakh, Saulius Cicenas, Skaidrius Miliauskas, Alexandru Calin Grigorescu, Carina Hillenbach, Hrefna Kristin Johannsdottir, Barbara Klughammer, a Emilio Esteban Gonzalez. "Efficacy and Safety of Erlotinib Versus Chemotherapy in Second-line Treatment of Patients with Advanced, Non-small-cell Lung Cancer with Poor Prognosis (TITAN): A Randomised Multicentre, Open-label, Phase 3 Study." The Lancet Oncology 13, no. 3 (2012): 300-308. https://doi.org/10.1016/S1470-2045(11)70385-0.
Citace podle MLA (9th ed.)Ciuleanu, Tudor, et al. "Efficacy and Safety of Erlotinib Versus Chemotherapy in Second-line Treatment of Patients with Advanced, Non-small-cell Lung Cancer with Poor Prognosis (TITAN): A Randomised Multicentre, Open-label, Phase 3 Study." The Lancet Oncology, vol. 13, no. 3, 2012, pp. 300-308, https://doi.org/10.1016/S1470-2045(11)70385-0.